Is Summit Therapeutics a Millionaire Maker? | The Motley Fool

Oct 27, 2024 · Still, shares of Summit Therapeutics (SMMT 3.63%) are up by more than 989% in the last 12 months as I write this, and that's reason enough for investors to wonder if it might be a stock that's ...

63%
OFF

Is Summit Therapeutics A Millionaire Maker? | The Motley Fool

2 weeks from now

fool.com

989%
OFF

Is Summit Therapeutics A Millionaire Maker? - Sharewise

2 weeks from now

Oct 27, 2024 · Still, shares of Summit Therapeutics (NASDAQ: SMMT) are up by more than 989% in the last 12 While the idea of getting rich quick is always appealing, it's seldom as …

sharewise.com

22%
OFF

Why Summit Therapeutics Stock Crushed The Market This Week

2 weeks from now

Mar 29, 2024 · One exceptional stock in the healthcare sector this trading week was Summit Therapeutics (SMMT-4.22%). Buoyed by encouraging news from the lab, the company got an …

fool.com

989%
OFF

Is Summit Therapeutics A Millionaire Maker? - Mitrade.com

2 weeks from now

Oct 27, 2024 · Is Summit Therapeutics a Millionaire Maker? Source The Motley Fool Still, shares of Summit Therapeutics (NASDAQ: SMMT) are up by more than 989% in the last 12 months …

mitrade.com

000%
OFF

Is Summit Therapeutics A Millionaire Maker? - Longportapp.com

2 weeks from now

Oct 5, 2024 · Summit Therapeutics has seen a 1,000% increase in stock value over the past year due to its oncology drug, ivonescimab, which is in phase 3 trials. The drug aims to compete …

longportapp.com

584%
OFF

Why Summit Therapeutics Rocketed 584% In 2024 - Yahoo Finance

2 weeks from now

1 day ago · Billy Duberstein, The Motley Fool . Wed, Jan 15, 2025, 6:35 AM 3 min read. In This Article: SMMT . Shares of biotech Summit Therapeutics (NASDAQ: SMMT) skyrocketed …

yahoo.com

700%
OFF

Up 700% This Year, Is It Too Late To Invest In This Stock?

2 weeks from now

Oct 15, 2024 · The Motley Fool has positions in and recommends Merck and Summit Therapeutics. The Motley Fool has a disclosure policy. Related Articles. Where Will Summit …

fool.com

584%
OFF

Why Summit Therapeutics Rocketed 584% In 2024 | The Motley Fool

2 weeks from now

1 day ago · Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More Why Summit …

fool.com

584%
OFF

Why Summit Therapeutics Rocketed 584% In 2024 - MSN

2 weeks from now

The Motley Fool has positions in and recommends Summit Therapeutics. The Motley Fool has a disclosure policy. Why Summit Therapeutics Rocketed 584% in 2024 ...

msn.com

FAQs about Is Summit Therapeutics a Millionaire Maker? | The Motley Fool Coupon?

Should you buy Summit Therapeutics?

An analyst initiated coverage of Summit Therapeutics with an enthusiastic buy recommendation. He feels its investigational cancer drug has vast potential. You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. ...

Is Summit Therapeutics a good Biotech stock to buy?

On the other hand, if you're a bit more patient, it's probably worth buying shares, especially if you're looking for a biotech stock that's slightly less risky than the average for its category. Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Summit Therapeutics. ...

Is Summit Therapeutics (SMMT) a good stock to buy?

Still, shares of Summit Therapeutics (SMMT 9.25%) are up by more than 989% in the last 12 months as I write this, and that's reason enough for investors to wonder if it might be a stock that's capable of making them millionaires in a relatively short time, and without much fuss. ...

Will Summit Therapeutics make significant progress in the next 5 years?

Summit Therapeutics should make significant progress in the next five years. Summit Therapeutics (SMMT -0.60%) has risen in prominence in the past two years thanks to a promising pipeline candidate, ivonescimab, a potential cancer treatment. The company's shares are up by 340% since January 2023. The market has high hopes for the biotech. ...

Why do insiders buy Summit Therapeutics stock?

At the end of March this year, Summit Therapeutics CEO and President Maky Zanganeh purchased over 110,000 shares on the public market through her revocable trust at an average price of $3.72. An old saying goes, insiders sell stock for many reasons, but generally buy for only one: They believe the stock is going up. ...

Does Eric Volkman have a position in Summit Therapeutics?

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Summit Therapeutics. The Motley Fool has a disclosure policy. The company was a standout in the biotech field, rising by nearly 23% over the period. ...